மார்ச்சு 25, 2023 இதழ்
தமிழ் வார இதழ்

I have in the past described each other agonist and you will antagonist homobivalent ligands emphasizing the melanocortin receptor program

வழக்கறிஞர் ராஜாசுந்தர் ராமன்

Apr 7, 2024

Overall performance

40–41 Ligands targeting the melanocortin system have been implicated as potential therapeutics or used as pharmacological probes for a wide range of disease states including cancer, 42–46 skin pigmentation disorders, 47 social disorders, 48–49 sexual function disorders, 50–52 Alzheimer’s disease, 53–54 cachexia, 55–59 and obesity. 40, 60–62 All five melanocortin receptor subtypes (MC1-5R) signal through the G?s protein signaling pathway. In this pathway, an agonist binding to the GPCR activates cAMP signal transduction pathways and also results in the recruitment of ?-arrestin. 63 The melanocortin-3 receptor (MC3R) and melanocortin-4 receptor (MC4R) in particular have been elucidated to play roles in energy homeostasis. 60–62, 64–65 Ligands for the MC4R were under intense clinical development to treat obesity and related metabolic disorders; however these ligands were reported to have undesirable effects such as https://kissbrides.com/no/osteuropeiske-kvinner/ increasing blood pressure 66 or inducing male erections. 67 It is hypothesized that ligands that target melanocortin homodimers may have unique effects from the current monovalent approaches, and may, therefore circumvent some side effects.

We have in the past found you to an enthusiastic agonist homobivalent ligand provides an effective line of into the vivo pharmacological character than the the monovalent counterpart recommending one targeting putative melanocortin dimers might have emotional relevance. 41 Furthermore, biased ligands would be valuable pharmacological probes to help you clarify and therefore signaling pathway accounts for the various melanocortin established outcomes (i.age. reduced meals versus improved blood pressure levels). In the present data, we report the proper execution and you can synthesis from MUmBLs to focus on asymmetrically signaling melanocortin homodimers. The newest ligands discover using this underappreciated therapeutic biochemistry approach had a great biased agonist pharmacology not said in the books up until now. They potently activated new go camping signaling path with just minimal activation out of the newest ?-arrestin employment path. The present day analysis provides book unit probes towards the melanocortin receptors including a call at vitro proof-of-concept of utilizing the biased unmatched bivalent ligand (BUmBL) build option to target asymmetrically signaling homodimers. Which innovative construction method might be applied to individuals GPCR possibilities with the production of biased ligands.

Framework and Synthesis away from MUmBLs

fourteen to twenty five-fold) consistent with a synergistic joining mode arising from receptor dimer joining. 38, 40–41, 46, 68–75 Despite increased binding affinities, we have observed much shorter bend grows for the functional potencies regarding agonist homobivalent ligands whenever analyzed thru camp-created useful assays (3- to 5-fold). forty Brabez and you will coworkers provides noted similar effects having agonist melanocortin bivalent ligands where go camping buildup wasn’t just like the significantly improved which have involved multivalent binding. 46 You to definitely chance of the new incongruity between binding affinity expands and you will useful signaling grows that have bivalent ligands is generally on account of allosterism involving the melanocortin receptors in this homodimers. forty For example asymmetric signaling within GPCR homodimers has before already been claimed many different assistance for instance the vasopressin, twenty-eight dopamine, a dozen adenosine, 26 metabotropic glutamate, 19 and serotonin receptors. 13

An alternate paradigm are hypothesized in which one receptor inside the fresh melanocortin homodimer was responsible for go camping signaling as well as the most other receptor could well be accountable for signaling owing to a separate cellular pathway (elizabeth.g. ?-arrestin recruitment pathway) ( Figure 1A–B ). It might upcoming realize that the enhanced binding would not always lead to a rise in useful agonist activity seen in a camp assay, as effectation of next binding event isn’t imagined through this cellular assay paradigm. Also, there had been records from asymmetry inside melanocortin homodimers both in binding studies and practical assays. 27, 76–78 So you’re able to exploit so it chances of asymmetric homodimers, i customized and you may synthesized MUmBLs you to contained the fresh identified agonist melanocortin moiety His-DPhe-Arg-Trp on one hand of your molecule, 79–80 and identified MC3R and you will MC4R antagonist moiety Their-DNal(2?)-Arg-Trp 81–82 on the other hand of one’s molecule linked of the around three more prior to now validated linker options ( Dining table step one ). 38, 40, 70, 83


வழக்கறிஞர் ராஜாசுந்தர் ராமன்

இவரது மற்ற கட்டுரைகளைக் காண இங்கே சொடுக்குங்கள்.

கருத்துக்கள் பதிவாகவில்லை- “I have in the past described each other agonist and you will antagonist homobivalent ligands emphasizing the melanocortin receptor program”

அதிகம் படித்தது